Primary Brain Tumors in Adults: Advances in Mechanistic Understanding, Evaluation, and Management

Primary Brain Tumors in Adults: Advances in Mechanistic Understanding, Evaluation, and Management, Volume 166 in the Advances in Cancer Research series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Molecular drivers in primary brain tumor formation, Novel CSF pathways in the glioma (DIPG), Volumetric analysis in low grade gliomas and other advanced MR imaging techniques, Liquid biopsy in the diagnosis of primary brain tumors, Intraoperative imaging techniques to improve tumor detection, and much more.

Additional chapters focus on Supramaximal resection in primary brain tumors, Radiotherapeutic approaches: IMRT, re-irradiation, Molecularly driven therapies in the treatment of primary brain tumors, and Changes in the immune microenvironment and immunotherapeutic strategies in the treatment of gliomas.

PF

Paul B. Fisher

Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).

Affiliations and expertise

Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USA

PF

Paul B. Fisher

Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).

Affiliations and expertise

Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USA

MD

Mariza Daras

Dr. Mariza Daras is an Associate professor in the Department of Neurosurgery and the Chief of Neuro-oncology at Virginia Commonwealth University’s Massey Comprehensive Cancer Center in Richmond, Virginia. She began her academic medical career at Columbia College of Physicians and Surgeons, where she received her medical degree. After completing her Neurology residency at Duke University Medical Center and a Neuro-oncology fellowship at Memorial Sloan Kettering, she served as faculty in the Department of Neurology at Memorial Sloan Kettering. She subsequently took on a faculty position in the Division of Neuro-oncology at the University of California San Francisco where she spearheaded a CNS metastasis multidisciplinary program. In 2019, she joined VCU to lead the Division of Neuro-oncology. Dr. Daras has focused her research efforts on clinical trials for patients with primary and metastatic brain tumors, and specifically in the development of novel immunotherapeutic and combinatorial strategies. She has also dedicated her time to teaching and mentoring medical school students, residents, fellows, and advanced practice providers and is the Program Director of the VCU neuro-oncology fellowship. She is board-certified by the American Board of Psychiatry and Neurology and the United Council of Neurologic Subspecialties for neuro-oncology. Dr. Daras is a member of the American Academy of Neurology (AAN), Society for Neuro-Oncology (SNO), and American Society of Clinical Oncology (ASCO). She is an appointed member of AAN’s Committee on Public Engagement, as well as the AAN, Committee on Brain Health. She also serves as appointed member of the SNO Diversity and Women Committee, as well as the SNO/ASCO CNS Metastases Annual Conference.

Affiliations and expertise

Associate Professor, Department of Neurosurgery, Chief of Neuro-oncology, Virginia Commonwealth University’s Massey Comprehensive Cancer Center in Richmond, Virginia, USA

KT

Kenneth D. Tew

Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA

The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.

Affiliations and expertise

Professor and Chairman, Department of Cell and Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Primary Brain Tumors in Adults: Advances in Mechanistic Understanding, Evaluation, and Management

Purchase options

Innovate. Sustain. Transform.

Institutional subscription on ScienceDirect

Paul B. Fisher

Paul B. Fisher

Mariza Daras

Kenneth D. Tew